Skip to main content
SpringerLink
Log in

Systemic Therapies for Acne

  • Chapter
  • First Online:
Book cover Acneiform Eruptions in Dermatology

  • 1770 Accesses

Abstract

Individuals with moderate-to-severe inflammatory acne may warrant systemic therapies, especially if they are unresponsive to topical treatments, or have significant quality of life decrements, which is not uncommon in this population. Specific clinical features, including the type and severity of acne, the presence of scarring, and the association with abnormal menses, can help guide the appropriate course of treatment. All dosages mentioned in this section must be adjusted according to the individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin. 2009;27:33–42.

    Article  PubMed  Google Scholar 

  2. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1–37.

    Article  PubMed  Google Scholar 

  3. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(3):S200–10.

    Article  PubMed  Google Scholar 

  4. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651–63.

    Article  PubMed  Google Scholar 

  5. Rafiei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne vulgaris. J Dermatolog Treat. 2006;17:217–21.

    Article  PubMed  CAS  Google Scholar 

  6. Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2005;30:215–20.

    Article  PubMed  CAS  Google Scholar 

  7. Antonio JR, Pegas JR, Cestari T, Do Nascimento LV. Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety. J Dermatolog Treat. 2008; 19:210–5.

    Article  PubMed  CAS  Google Scholar 

  8. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79:9–25.

    PubMed  Google Scholar 

  9. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol. 1990;122:233–44.

    Article  PubMed  CAS  Google Scholar 

  10. Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline but sensitive to minocycline. Br J Dermatol. 1993; 128:556–60.

    Article  PubMed  CAS  Google Scholar 

  11. Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Coch Data Syst Rev. 2003; Issue 1: CD002086.

    Google Scholar 

  12. McManus P, Iheanacho I. Don’t use minocycline as first line oral antibiotic in acne. BMJ. 2007;334:154.

    Article  PubMed  Google Scholar 

  13. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459–64.

    Article  PubMed  CAS  Google Scholar 

  14. Stewart DM, Torok HM, Weiss JS, et al. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis. 2006;78:11–20.

    PubMed  Google Scholar 

  15. Fleischer Jr AB, Dinehart S, Stough D, et al. Safety and efficacy of a new extended-release formulation of minocycline for acne vulgaris. Cutis. 2006;78:21–31.

    PubMed  Google Scholar 

  16. Sturkenboom MC, Meier CR, Jick H, Striker BH. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med. 1999;159:493–7.

    Article  PubMed  CAS  Google Scholar 

  17. Fanelli M, Kupperman E, Lautenbach E, Edelstein PH, Margolis DJ. Antibiotics, acne, and staphylococcus aureus colonization. Arch Dermatol. 2011;147:917–21.

    Article  PubMed  Google Scholar 

  18. Bhambri S, Del Rosso JQ, Desai A. Oral trimethoprim/sulfamethoxazole in the treatment of acne vulgaris. Cutis. 2007;79(6):430–4.

    PubMed  Google Scholar 

  19. Amnesteem® (Isotretinoin Capsules USP) [package insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc. 2010.

    Google Scholar 

  20. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10:490–6.

    Article  PubMed  CAS  Google Scholar 

  21. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001;45(5):S150–7.

    Article  PubMed  CAS  Google Scholar 

  22. White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol. 1998;134:376–8.

    Article  PubMed  CAS  Google Scholar 

  23. Azoulay L, Oraichi D, Bérard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol. 2007;157(6):1240–8.

    Article  PubMed  CAS  Google Scholar 

  24. Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med. 1985;313:981–5.

    Article  PubMed  CAS  Google Scholar 

  25. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985; 313:837–41.

    Article  PubMed  CAS  Google Scholar 

  26. Adams J, Lammer EJ. Neurobehavioral teratology of isotretinoin. Reprod Toxicol. 1993; 7:175–7.

    Article  PubMed  CAS  Google Scholar 

  27. Margolis DJ, Attie M, Leyden JJ. Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin therapy for acne vulgaris. Arch Dermatol. 1996;132:769–74.

    Article  PubMed  CAS  Google Scholar 

  28. Reddy D, Siegel CA, Sands BE, et al. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol. 2006;101:1569–73.

    Article  PubMed  CAS  Google Scholar 

  29. Azoulay L, Blais L, Koren G, et al. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry. 2008;69:526–32.

    Article  PubMed  CAS  Google Scholar 

  30. Crockett SD, Gulati A, Sandler RS, et al. A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol. 2009;104: 2387–93.

    Article  PubMed  Google Scholar 

  31. Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol. 2008;144: 1197–9.

    Article  PubMed  Google Scholar 

  32. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg. 2007;26:210–20.

    Article  PubMed  CAS  Google Scholar 

  33. Chia CY, Lane W, Chibnall J, et al. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Arch Dermatol. 2005;141:557–60.

    Article  PubMed  CAS  Google Scholar 

  34. Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. Med Clin North Am. 2009; 93:1161–81.

    Article  PubMed  CAS  Google Scholar 

  35. Kelekci KH, Kelekci S, Incki K, et al. Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne. Int J Dermatol. 2010; 49:775–9.

    PubMed  Google Scholar 

  36. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292:726–35.

    Article  PubMed  CAS  Google Scholar 

  37. Junkins-Hopkins JM. Hormone therapy for acne. J Am Acad Dermatol. 2010;62(3):486–8.

    Article  PubMed  Google Scholar 

  38. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Coch Data Syst Rev. 2009; Issue 3: CD004425.

    Google Scholar 

  39. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74:123–30.

    PubMed  Google Scholar 

  40. Yaz® (Drospirenone/Ethinyl estradiol) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc.: 2011.

    Google Scholar 

  41. Castelli WP. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke. Am J Obstet Gynecol. 1999;180:S349–56.

    Article  PubMed  CAS  Google Scholar 

  42. Helms SE, Bredle DL, Zajic J, Jatjoura D, Brodell RT, Krishnarao I. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 1997;36:705–10.

    Article  PubMed  CAS  Google Scholar 

  43. Dickinson BD, Altman RD, Nielsen NH, Sterling ML, Council on Scientific Affairs, American Medical Association. Interactions between oral contraceptives and antibiotics. Obstet Gynecol. 2001;98:853–60.

    Article  PubMed  CAS  Google Scholar 

  44. Berenson AB, Odom SD, Breitkopf CR, Rahman M. Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills. Am J Obstet Gynecol. 2008;199:351.e1–e12.

    Article  Google Scholar 

  45. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111:209–14.

    Article  PubMed  CAS  Google Scholar 

  46. Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Coch Data Syst Rev. 2009; Issue 2:CD000194.

    Google Scholar 

  47. Saint-Jean M, Ballanger F, Nguyen J, Khammari A, Dréno B. Importance of spironolactone in the treatment of acne in adult women. J Eur Acad Dermatol Venereol. 2010;25:1480–1. doi:10.1111/j.1468-3083.2010.03926.x.

    Article  PubMed  Google Scholar 

  48. Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227–32.

    Article  PubMed  CAS  Google Scholar 

  49. Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol. 1985;112:124–5.

    Article  PubMed  CAS  Google Scholar 

  50. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43:498–502.

    Article  PubMed  CAS  Google Scholar 

  51. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol. 2010;28:17–23.

    Article  PubMed  Google Scholar 

  52. Van Wayjen R, van den Ende A. Experience in the long term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic, and endocrine effects. Exp Clin Endocrinol Diabetes. 1995;103:241–51.

    Article  PubMed  Google Scholar 

  53. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22:419–28.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Massachusetts General Hospital, 50 Staniford Street Suite 240, Boston, MA, 02114, USA

    Marisa Kardos Garshick B.S., Alexa Kimball M.D., M.P.H. & Lynn Drake M.D.

Authors
  1. Marisa Kardos Garshick B.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexa Kimball M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lynn Drake M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marisa Kardos Garshick B.S. .

Editor information

Editors and Affiliations

  1. Mount Sinai Medical Center, New York, USA

    Joshua Zeichner

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Garshick, M.K., Kimball, A., Drake, L. (2014). Systemic Therapies for Acne. In: Zeichner, J. (eds) Acneiform Eruptions in Dermatology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8344-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8344-1_4

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8343-4

  • Online ISBN: 978-1-4614-8344-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation